Resistance to Lefamulin: An Evaluation of Data from In Vitro Antimicrobial Susceptibility Studies
Antibiotics · 05.01.2026 · 15 (1) · 58
DOI: 10.3390/antibiotics15010058 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 05.01.2026. Verfasst von Matthew E Falagas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Alfa Institute of Biomedical Sciences (AIBS), 151 23 Athens, Greece. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lefamulin, a new, first-in-class pleuromutilin antibiotic, was recently approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of patients with community-acquired bacterial pneumonia (CABP). In this context, this review aimed to evaluate its activity against the most common pathogens causing this infection. A thorough search was performed in five databases (Embase, Scopus, Web of Science, PubMed, PubMed Central) from their inception to 14th of October 2025. Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) resistance breakpoints were applied. Out of a total of 224 articles identified, 11 were deemed eligible for inclusion. Resistance among Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus isolates was 0–2.6%, 0–2.4%, and 0–4.3%, respectively. Even among isolates with specific mechanisms of resistance, such as β-lactamase-producing H. influenzae and methicillin-resistant S. aureus, resistance was below 2.4% and 3.4%, respectively. Among isolates for which no breakpoints were available (Moraxella catarrhalis, atypical pathogens, Enterococcus spp., Streptococcus spp., Haemophilus spp., and Staphylococcus spp.), MIC90 values were low. An exception were isolates belonging to Enterococcus spp., which displayed MIC90 values ranging from 0.25 to >16 mg/L in the two studies with relevant data. Lefamulin demonstrated broad in vitro activity against key pathogens causing CABP, making it a considerable addition to the therapeutic options for such infections, especially in cases where first-line agents cannot be used for reasons such as allergy or previous failure.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Alfa Institute of Biomedical Sciences (AIBS), 151 23 Athens, Greece.
- Department of Medicine, School of Medicine, European University Cyprus, Nicosia 1516, Cyprus.
- Department of Medicine, School of Medicine, Tufts University, Boston 02111, MA, USA.
- Department of Medicine, Hygeia Hospital, 151 23 Athens, Greece.
Zitieren
APA
Falagas, M. E., Fanariotis, G., Romanos, L. T., Katsikas, K. M., & Kakoullis, S. A. (2026). Resistance to Lefamulin: An Evaluation of Data from In Vitro Antimicrobial Susceptibility Studies. Antibiotics, 15(1), 58. https://doi.org/10.3390/antibiotics15010058
Vancouver
Falagas ME, Fanariotis G, Romanos LT, Katsikas KM, Kakoullis SA. Resistance to Lefamulin: An Evaluation of Data from In Vitro Antimicrobial Susceptibility Studies. Antibiotics. 2026;15(1):58. doi:10.3390/antibiotics15010058
BibTeX
@article{Falagas2026,
author = {Falagas, Matthew E and Fanariotis, George and Romanos, Laura T and Katsikas, Konstantinos M and Kakoullis, Stylianos A},
title = {Resistance to Lefamulin: An Evaluation of Data from In Vitro Antimicrobial Susceptibility Studies},
journal = {Antibiotics},
year = {2026},
volume = {15},
number = {1},
pages = {58},
doi = {10.3390/antibiotics15010058}
}
EUVIMED